Bruce Neal's Publications

About Bruce Neal's Publications

Executive Director, The George Institute for Global Health, Australia

  • EFFECTS OF SGLT2 INHIBITORS ON STROKE IN TYPE 2 DIABETES ACCORDING TO BASELINE KIDNEY FUNCTION

    Journal of the American College of Cardiology Date published:

  • EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL

    Journal of the American College of Cardiology Date published:

  • EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL

    Journal of the American College of Cardiology Date published:

  • Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials

    BMJ Date published:

  • A Community-Based Intervention for Managing Hypertension in Rural South Asia

    New England Journal of Medicine Date published:

  • Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

    Journal of the American Heart Association Date published:

  • Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%

    Circulation Date published:

  • Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017

    The Lancet Date published:

  • Sources of dietary sodium and implications for a statewide salt reduction initiative in Victoria, Australia

    British Journal of Nutrition Date published:

  • Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program

    Diabetes, Obesity and Metabolism Date published:

  • Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes

    JACC: Heart Failure Date published:

  • Contribution of major food companies and their products to household dietary sodium purchases in Australia

    Unknown Date published:

  • Amino-Terminal Pro-B Type Natriuretic Peptide in the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program

    Date published:

  • The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program

    The Lancet Rheumatology Date published:

  • Front-of-pack nutrition labelling to promote healthier diets: current practice and opportunities to strengthen regulation worldwide

    BMJ Global Health Date published:

  • Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c < 7%: Results From the CREDENCE Trial

    Date published: